BCL2 and acute lymphoblastic leukemia: More strikingly, the therapeutic pressure of BCL2 inhibitors induces transcriptional remodeling of the residual T-ALL cells within the splenic niche, revealing the spleen as a potential site of chemoresistance and disease relapse [61].